Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer

BACKGROUND: Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)‐high or mismatch repair‐deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies. METHODS: We performed a single institution retrospective revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tucker, Matthew D., Zhu, Jason, Marin, Daniele, Gupta, Rajan T., Gupta, Santosh, Berry, William R., Ramalingam, Sundhar, Zhang, Tian, Harrison, Michael, Wu, Yuan, Healy, Patrick, Lisi, Stacey, George, Daniel J., Armstrong, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712455/
https://www.ncbi.nlm.nih.gov/pubmed/31270961
http://dx.doi.org/10.1002/cam4.2375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712455/
https://www.ncbi.nlm.nih.gov/pubmed/31270961
http://dx.doi.org/10.1002/cam4.2375

Ejemplares similares